BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.50+0.05 (+0.67%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
BioCryst Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
BioCryst Pharmaceuticals's total assets was $557.85M at Jun 30, 2026. For fiscal 2025 it was $514.16M, up 4.8% from the year before. Over ten years it grew 15.4% a year on average. The highest annual figure on record is $588.15M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $514.16M | +4.8% |
| FY2024 | Dec 31, 2024 | $490.42M | -5.1% |
| FY2023 | Dec 31, 2023 | $516.96M | -6.0% |
| FY2022 | Dec 31, 2022 | $550.00M | -6.5% |
| FY2021 | Dec 31, 2021 | $588.15M | +75.7% |
| FY2020 | Dec 31, 2020 | $334.72M | +91.0% |
| FY2019 | Dec 31, 2019 | $175.28M | +19.4% |
| FY2018 | Dec 31, 2018 | $146.84M | -17.6% |
| FY2017 | Dec 31, 2017 | $178.26M | +98.4% |
| FY2016 | Dec 31, 2016 | $89.85M | -26.6% |
| FY2015 | Dec 31, 2015 | $122.36M | -10.6% |
| FY2014 | Dec 31, 2014 | $136.87M | +180.1% |
| FY2013 | Dec 31, 2013 | $48.87M | -14.9% |
| FY2012 | Dec 31, 2012 | $57.44M | -30.1% |
| FY2011 | Dec 31, 2011 | $82.21M | -24.9% |
| FY2010 | Dec 31, 2010 | $109.45M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $557.85M | +22.0% |
| Q1 FY2026 | Mar 31, 2026 | $465.05M | -3.1% |
| Q4 FY2025 | Dec 31, 2025 | $514.16M | +4.8% |
| Q3 FY2025 | Sep 30, 2025 | $446.42M | -9.1% |
| Q2 FY2025 | Jun 30, 2025 | $457.19M | -3.2% |
| Q1 FY2025 | Mar 31, 2025 | $480.05M | +2.6% |
| Q4 FY2024 | Dec 31, 2024 | $490.42M | -5.1% |
| Q3 FY2024 | Sep 30, 2024 | $491.25M | -6.1% |
| Q2 FY2024 | Jun 30, 2024 | $472.42M | -10.8% |
| Q1 FY2024 | Mar 31, 2024 | $467.89M | -8.2% |
| Q4 FY2023 | Dec 31, 2023 | $516.96M | -6.0% |
| Q3 FY2023 | Sep 30, 2023 | $522.92M | -6.4% |
| Q2 FY2023 | Jun 30, 2023 | $529.89M | +3.8% |
| Q1 FY2023 | Mar 31, 2023 | $509.74M | -3.4% |
| Q4 FY2022 | Dec 31, 2022 | $550.00M | -6.5% |
| Q3 FY2022 | Sep 30, 2022 | $558.59M | +110.2% |
| Q2 FY2022 | Jun 30, 2022 | $510.54M | +84.1% |
| Q1 FY2022 | Mar 31, 2022 | $527.72M | +85.5% |
| Q4 FY2021 | Dec 31, 2021 | $588.15M | +75.7% |
| Q3 FY2021 | Sep 30, 2021 | $265.76M | +50.8% |
| Q2 FY2021 | Jun 30, 2021 | $277.28M | +29.1% |
| Q1 FY2021 | Mar 31, 2021 | $284.43M | +108.2% |
| Q4 FY2020 | Dec 31, 2020 | $334.72M | +91.0% |
| Q3 FY2020 | Sep 30, 2020 | $176.23M | +94.7% |
| Q2 FY2020 | Jun 30, 2020 | $214.71M | +84.5% |
| Q1 FY2020 | Mar 31, 2020 | $136.59M | -4.0% |
| Q4 FY2019 | Dec 31, 2019 | $175.28M | +19.4% |
| Q3 FY2019 | Sep 30, 2019 | $90.50M | -46.2% |
| Q2 FY2019 | Jun 30, 2019 | $116.34M | -14.9% |
| Q1 FY2019 | Mar 31, 2019 | $142.34M | -8.4% |
| Q4 FY2018 | Dec 31, 2018 | $146.84M | -17.6% |
| Q3 FY2018 | Sep 30, 2018 | $168.31M | -12.1% |
| Q2 FY2018 | Jun 30, 2018 | $136.64M | +20.4% |
| Q1 FY2018 | Mar 31, 2018 | $155.37M | +20.0% |
| Q4 FY2017 | Dec 31, 2017 | $178.26M | +98.4% |
| Q3 FY2017 | Sep 30, 2017 | $191.49M | +109.3% |
| Q2 FY2017 | Jun 30, 2017 | $113.51M | – |
| Q1 FY2017 | Mar 31, 2017 | $129.51M | – |
| Q4 FY2016 | Dec 31, 2016 | $89.85M | – |
| Q3 FY2016 | Sep 30, 2016 | $91.50M | – |
See a number that looks wrong?